Olinvacimab (TTAC-0001) is a fully human monoclonal antibody targeting VEGFR2, exhibiting potent antiangiogenic properties. This antibody binds specifically to the kinase insert domain receptor (KDR), a known alias for VEGFR2, with a high affinity characterized by a dissociation constant (Kd) of 0.23 nM. By inhibiting the vascular endothelial growth factor (VEGF) pathway, Olinvacimab effectively disrupts tumor angiogenesis. It is primarily utilized in research focused on investigating therapeutic approaches for recurrent glioblastoma and breast cancer.
Olinvacimab (TTAC-0001) is a fully human monoclonal antibody targeting VEGFR2, exhibiting potent antiangiogenic properties. This antibody binds specifically to the kinase insert domain receptor (KDR), a known alias for VEGFR2, with a high affinity characterized by a dissociation constant (Kd) of 0.23 nM. By inhibiting the vascular endothelial growth factor (VEGF) pathway, Olinvacimab effectively disrupts tumor angiogenesis. It is primarily utilized in research focused on investigating therapeutic approaches for recurrent glioblastoma and breast cancer.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
